Int J Stomatol

Int J Stomatol ›› 2019, Vol. 46 ›› Issue (5): 609-616.doi: 10.7518/gjkq.2019057

• Reviews • Previous Articles     Next Articles

Oral chronic graft versus host disease

Zhou Yuxi,Yong Xiangzhi,Jiang Qiaozhi,Tao Renchuan()   

  1. Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Medical University, Nanning 530021, China
  • Received:2018-11-17 Revised:2019-05-26 Online:2019-09-01 Published:2019-09-10
  • Contact: Renchuan Tao E-mail:dr.taorc@foxmail.com
  • Supported by:
    This study was supported by National Natural Science Foundation of China(81771073);Natural Science Foundation of Guangxi Province(2015GXNSFDA139018)

RichHTML

14

PDF (PC)

693

Abstract:

Chronic graft versus host disease (cGVHD) is a syndrome that manifests as an autoimmune disease. Oral lesions, called oral cGVHD, can exist independently and often present as chronic inflammation of the oral mucosa and salivary gland fibrosis. Timely and effective diagnosis and treatment of oral cGVHD can help reduce the suffering of patients and improve their quality of life. However, current understanding of oral cGVHD pathogenesis is limited. This review focuses on the progress of the clinical manifestations, pathological manifestations, pathogenesis, and treatment of oral cGVHD.

Key words: oral chronic graft versus host disease, clinical manifestations, pathological manifestations, pathogenesis, treatment

CLC Number: 

  • R781.5 +9

TrendMD: 

Tab 1

Oral characterization score for oral cGVHD patients"

口腔黏膜的改变 轻度 计分 中度 计分 重度 计分
红斑 轻度或中度红斑样改变（<25%） 1 中度（≥25%）或重度（<25%）红斑样改变 2 重度红斑样改变（≥25%） 3
苔藓样变 苔藓样变（<25%） 1 苔藓样变（25%~50%） 2 苔藓样变（>50%） 3
溃疡 无 0 溃疡（<20%） 3 严重溃疡（>20%） 6
[1] Lee SJ, Vogelsang G, Flowers ME . Chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2003,9(4):215-233.
[2] Filipovich AH, Weisdorf D, Pavletic S , et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease:Ⅰ. Diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2005,11(12):945-956.
[3] Jagasia MH, Greinix HT, Arora M , et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease:Ⅰ. The 2014 diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2015, 21(3): 389- 401. e1.
[4] Treister N, Duncan C, Cutler C , et al. How we treat oral chronic graft-versus-host disease[J]. Blood, 2012,120(17):3407-3418.
[5] Bassim CW, Fassil H, Mays JW , et al. Oral disease profiles in chronic graft versus host disease[J]. J Dent Res, 2015,94(4):547-554.
[6] 陈谦明 . 口腔黏膜病学[M]. 4版. 北京: 人民卫生出版社, 2014: 1-242.
Chen QM. Diseases of oral mucosa[M]. 4th ed. Beijing: People’s Medical Publishing House, 2014: 1-242.
[7] Nagler RM, Nagler A . The molecular basis of salivary gland involvement in graft--vs.--host disease[J]. J Dent Res, 2004,83(2):98-103.
[8] Meier JK, Wolff D, Pavletic S , et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD[J]. Clin Oral Investig, 2011,15(2):127-139.
[9] Balasubramaniam R, Alawi F , DeRossi S. Superficial mucoceles in chronic graft-versus-host disease: a case report and review of the literature[J]. Gen Dent, 2009,57(1):82-88.
[10] Imanguli MM, Alevizos I, Brown R , et al. Oral graft-versus-host disease[J]. Oral Dis, 2008,14(5):396-412.
[11] Schubert MM , Correa ME. Oral graft-versus-host disease[J]. Dent Clin North Am, 2008, 52(1): 79-109, viii-ix.
[12] Morton LM, Saber W, Baker KS , et al. National Institutes of Health hematopoietic cell transplantation late effects initiative: the subsequent neoplasms working group report[J]. Biol Blood Marrow Transplant, 2017,23(3):367-378.
[13] Weng X, Xing Y, Cheng B . Multiple and recurrent squamous cell carcinoma of the oral cavity after graft- versus-host disease[J]. J Oral Maxillofac Surg, 2017,75(9):1899-1905.
[14] Elad S, Zadik Y, Zeevi I , et al. Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an increased risk for recurrence[J]. Transplantation, 2010,90(11):1243-1244.
[15] Khan FM, Sy S, Louie P , et al. Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with a history of chronic graft-versus-host disease, and rare in nasal mucosa[J]. Blood, 2010,116(10):1803-1806.
[16] Theofilou VI, Sklavounou A, Argyris PP , et al. Oral verruciform xanthoma within lichen planus: a case report and literature review[J]. Case Rep Dent, 2018,2018:1615086.
[17] Marques YM, de Andrade CR, Machado de Sousa SC , et al. Oral verruciform xanthoma: a case report and literature review[J]. Case Rep Pathol, 2014,2014:641015.
[18] Aggarwal S, Aggarwal A, Gill S , et al. Verruciform xanthoma of oral cavity-a case report[J]. J Clin Diagn Res, 2014, 8(7): FD11-FD12.
[19] Shulman HM, Kleiner D, Lee SJ , et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: Ⅱ. Pathology Working Group Report[J]. Biol Blood Marrow Transplant, 2006,12(1):31-47.
[20] Soares AB, Faria PR, Magna LA , et al. Chronic GVHD in minor salivary glands and oral mucosa: histopathological and immunohistochemical evaluation of 25 patients[J]. J Oral Pathol Med, 2005,34(6):368-373.
[21] Imanguli MM, Atkinson JC, Mitchell SA , et al. Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation[J]. Biol Blood Marrow Transplant, 2010,16(10):1362-1369.
[22] Mays JW, Fassil H, Edwards DA , et al. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research[J]. Oral Dis, 2013,19(4):327-346.
[23] 龚非力 . 医学免疫学[M]. 2版. 北京: 科学出版社, 2007: 1-220.
Gong FL. Medical immunology[M]. 2nd ed. Beijing: China Science Publishing, 2007: 1-220.
[24] Sato M, Tokuda N, Fukumoto T , et al. Immunohistopathological study of the oral lichenoid lesions of chronic GVHD[J]. J Oral Pathol Med, 2006,35(1):33-36.
[25] Motta A, Zhan Q, Larson A , et al. Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: a pilot study[J]. Oral Dis, 2018,24(4):580-590.
[26] Matsuoka K, Koreth J, Kim HT , et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease[J]. Sci Transl Med, 2013, 5(179): 179ra43.
[27] Hayashida JN, Nakamura S, Toyoshima T , et al. Possible involvement of cytokines, chemokines and chemokine receptors in the initiation and progression of chronic GVHD[J]. Bone Marrow Transplant, 2013,48(1):115-123.
[28] 彭艳, 雍翔智, 冯豆豆 , 等. 口腔慢性移植物抗宿主病患者唾液T细胞相关细胞因子的表达水平[J]. 国际口腔医学杂志, 2016,43(5):524-527.
Peng Y, Yong XZ, Feng DD , et al. Salivary T cell cytokine expression in oral chronic graft-versus-host-disease[J]. Int J Stomatol, 2016,43(5):524-527.
[29] Fall-Dickson JM, Mitchell SA, Marden S , et al. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2010,16(7):948-956.
[30] Devic I, Shi M, Schubert MM , et al. Proteomic analysis of saliva from patients with oral chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2014,20(7):1048-1055.
[31] Imanguli MM, Swaim WD, League SC , et al. Increased T-bet + cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa [J]. Blood, 2009,113(15):3620-3630.
[32] Dander E, Balduzzi A, Zappa G , et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation[J]. Transplantation, 2009,88(11):1261-1272.
[33] 彭艳 . 异基因造血干细胞移植后口腔cGVHD患者T细胞相关细胞因子表达水平的初步研究[D]. 南宁: 广西医科大学, 2016.
Peng Y . Analysis of T-cell cytokines among patients with oral chronic graft-versus-host-disease after allogeneic hematopoietic stem cell transplantation[D]. Nanning: Guangxi Medical University, 2016.
[34] Chen X, Vodanovic-Jankovic S, Johnson B , et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease[J]. Blood, 2007,110(10):3804-3813.
[35] Zorn E, Kim HT, Lee SJ , et al. Reduced frequency of FOXP3 + CD4 +CD25 + regulatory T cells in patients with chronic graft-versus-host disease [J]. Blood, 2005,106(8):2903-2911.
[36] Koreth J, Kim HT, Jones KT , et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease[J]. Blood, 2016,128(1):130-137.
[37] Greinix HT, Pohlreich D, Kouba M , et al. Elevated numbers of immature/transitional CD21 - B lymphocytes and deficiency of memory CD27 + B cells identify patients with active chronic graft-versus-host disease [J]. Biol Blood Marrow Transplant, 2008,14(2):208-219.
[38] Sarantopoulos S, Stevenson KE, Kim HT , et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease[J]. Blood, 2009,113(16):3865-3874.
[39] Young JS, Wu T, Chen Y , et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4 + T cells that mediate autoimmune-like chronic graft-versus-host disease [J]. J Immunol, 2012,189(1):222-233.
[40] Nakamura S, Hiroki A, Shinohara M , et al. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1996,82(5):556-563.
[41] Mackay F, Silveira PA, Brink R . B cells and the BAFF/ APRIL axis: fast-forward on autoimmunity and signaling[J]. Curr Opin Immunol, 2007,19(3):327-336.
[42] Khoder A, Sarvaria A, Alsuliman A , et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD[J]. Blood, 2014,124(13):2034-2045.
[43] Correia-Silva Jde F, Victória JM, Guimarães AL , et al. Cytomegalovirus shedding in the oral cavity of allogeneic haematopoietic stem cell transplant patients[J]. Oral Dis, 2007,13(2):163-169.
[44] Orti-Raduan ES, Nunes AJ, Oliveira DT , et al. Quantitative analysis of Langerhans’ cells in oral chronic graft-vs.-host disease[J]. J Oral Pathol Med, 2009,38(1):132-137.
[45] Higaki Y, Yamada O, Okamura T , et al. Granzyme-B-containing lymphocyte involvement in epidermal injury in graft-versus-host disease[J]. Dermatology, 2001,202(2):94-98.
[46] Pimentel VN, de Matos LS, Soares TC , et al. Perforin and granzyme B involvement in oral lesions of lichen planus and chronic GVHD[J]. J Oral Pathol Med, 2010,39(10):741-746.
[47] Westekemper H, Meller S, Citak S , et al. Differential chemokine expression in chronic GVHD of the conjunctiva[J]. Bone Marrow Transplant, 2010,45(8):1340-1346.
[48] Croudace JE, Inman CF, Abbotts BE , et al. Chemokine-mediated tissue recruitment of CXCR3 + CD4 + T cells plays a major role in the pathogenesis of chronic GVHD [J]. Blood, 2012,120(20):4246-4255.
[49] Zadik Y, Elad S, Shapira A , et al. Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide[J]. Expert Opin Pharmacother, 2017,18(3):235-242.
[50] Elad S, Zeevi I, Finke J , et al. Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide-an open, randomized, multicenter study[J]. Biol Blood Marrow Transplant, 2012,18(1):134-140.
[51] Kuten-Shorrer M, Woo SB, Treister NS . Oral graft-versus-host disease[J]. Dent Clin North Am, 2014,58(2):351-368.
[52] Picardi A, Ferraro AS, Miranda M , et al. Therapeutic efficiency of platelet gel for the treatment of oral ulcers related to chronic graft versus host disease after allogeneic haematopoietic stem cell transplantation[J]. Oral Implantol (Rome), 2017,10(4):398-405.
[53] Bojanic I, Mravak Stipetic M , et al. Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft-versus-host disease[J]. Transfusion, 2018,58(6):1494-1499.
[54] Wolff D, Anders V, Corio R , et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease[J]. Photodermatol Photoimmunol Photomed, 2004,20(4):184-190.
[55] Richet C, Huynh A, Dimeglio C , et al. Extracorporeal photopheresis: an efficacious and well-tolerated treatment for cutaneous and oral mucosal chronic graft-versus-host disease[J]. Dermatology, 2018,234(1/2):23-30.
[56] Elad S, Or R, Shapira MY , et al. CO2 laser in oral graft-versus-host disease: a pilot study[J]. Bone Marrow Transplant, 2003,32(10):1031-1034.
[57] Epstein JB, Raber-Durlacher JE, Lill M , et al. Photobiomodulation therapy in the management of chronic oral graft-versus-host disease[J]. Support Care Cancer, 2017,25(2):357-364.
[1] Wang Nannan,He Hong,Hua Fang. Research progress on the risk factors of orthodontically induced enamel demineralization [J]. Int J Stomatol, 2024, 51(1): 91-98.
[2] Han Chong,He Dongning,Yu Feiyan,Wu Dongchao. Research progress on the mechanism and treatment of pain after oral implants [J]. Int J Stomatol, 2024, 51(1): 99-106.
[3] Xia Weiyao,Jia Zhonglin. Research progress on the relationship between vitamin and oral clefts [J]. Int J Stomatol, 2023, 50(6): 632-638.
[4] Sun Xu,Deng Zhennan,Wen Cai,Zhao Ying. Implant surface micromorphological changes after Er: YAG laser irradiation observed under scanning electron microscope [J]. Int J Stomatol, 2023, 50(6): 669-673.
[5] Huang Yuanhong,Peng Xian,Zhou Xuedong.. Progress in research into the effect of Rhizoma Drynariae on the treatment of bone-related diseases in the oral cavity [J]. Int J Stomatol, 2023, 50(6): 679-685.
[6] Liu Yang,Yin Deqiang. Introducing a novel digital articulation workflow with high precision [J]. Int J Stomatol, 2023, 50(5): 499-505.
[7] Ji Xiao,Zhang Lan,Huang Dingming.. Diagnosis and treatment of odontogenic and non-odontogenic maxillary sinusitis [J]. Int J Stomatol, 2023, 50(5): 566-572.
[8] Zhao Yuanxi,Su Qin.. Application and development of supplementary techniques in removing the remaining filling materials of root canal retreatment [J]. Int J Stomatol, 2023, 50(5): 581-586.
[9] Gong Meiling,Cheng Xingqun,Wu Hongkun.. Research progress on the correlation between Parkinson’s disease and periodontitis [J]. Int J Stomatol, 2023, 50(5): 587-593.
[10] Liu Ting,Wu Xiuping.. Research progress on oral-craniomaxillofacial features and treatment of Down syndrome [J]. Int J Stomatol, 2023, 50(5): 618-622.
[11] Qin Yichun,Tan Xuelian,Huang Dingming.. Clinical research progress on glandular odontogenic cyst [J]. Int J Stomatol, 2023, 50(1): 100-107.
[12] Li Ting,Yang Xuecai,Wang Junwei.. Children with Williams-Beuren syndrome associated with cranial and maxillofacial deformity [J]. Int J Stomatol, 2023, 50(1): 108-113.
[13] Wang Qiqiu,Zhi Qinghui.. Research progress on treatments of enamel white spot lesions [J]. Int J Stomatol, 2022, 49(6): 717-723.
[14] Li Weiguang,Wu Yafei,Guo Shujuan.. Research progress on the use of inorganic nanoparticles in the diagnosis and treatment of periodontal disease [J]. Int J Stomatol, 2022, 49(6): 724-730.
[15] Zhu Xingrong,Liao Lan. Research progress on oral clinical diagnosis and treatment of ectodermal dysplasia syndrome [J]. Int J Stomatol, 2022, 49(6): 737-742.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .